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Abstract Most early evolutionary thinkers came from
medicine, yet evolution has had a checkered history in
medical education. It is only in the last few decades that
serious efforts have begun to be made to integrate
evolutionary biology into the medical curriculum.
However, it is not clear when, where (independently or as
part of preclinical or clinical teaching courses) and, most
importantly, how should medical students learn the basic
principles of evolutionary biology applied to medicine,
known today as evolutionary or Darwinian medicine. Most
clinicians are ill-prepared to teach evolutionary biology and
most evolutionary biologists ill-equipped to formulate
clinical examples. Yet, if evolutionary science is to have
impact on clinical thought, then teaching material that
embeds evolution within the clinical framework must be
developed. In this paper, we use two clinical case studies to
demonstrate how such may be used to teach evolutionary
medicine to medical students in a way that is approachable
as well as informative and relevant.
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Introduction
Although many early evolutionary thinkers came from a
medical background, evolution has had a checkered history
in medical education. In the early nineteenth century,
Jean-Baptiste Lamarck and then Geoffroy St Hilaire
advocated “unity of composition” that ordered all living
organisms into a single chain of being (Appel 1987).
But forging a biological link from mollusks to kings
contravened contemporary religious dogmas and political
ideology. Hence, evolution was taught only in revolution-
ary France and radical schools, such as the University of
London (Desmond 1989). In the more liberal political
climate of the 1860s, the success of Darwin’s theory of
evolution by natural selection was followed by its
introduction into medical school courses, especially on
the European continent. At the University of Jena, medical
students first heard about evolution in their anatomical and
zoological courses, taught by the two most fervent
Darwinians in Continental Europe, Karl Gegenbaur and
Ernst Haeckel (Nyhart 1995). At the Vienna Institute of
Zootomy between 1861 and 1890, Carl Bernhard Brühl
offered courses in evolution to medical and science
students, as well as to the general public (Buklijas
2010). In the 1870s in Britain, Francis Maitland Balfour,
the first to teach embryology at Cambridge, used
Haeckel’s biogenetic law—the idea that embryos of higher
species in their development pass through adult stages of
lower species—to explain evolution (Blackman 2006). Yet
by the end of the nineteenth century, the medical
curriculum was in flux. New experimental sciences such
as physiology were vying for space with established
clinical and comparative disciplines such as anatomy
and zoology. Even evolution’s champion, “Darwin’s
bulldog” Thomas Huxley, who as president of the
Royal Society had considerable influence over the
content of medical education in this period, believed
evolution irrelevant to the problems doctors had to
address. The early twentieth-century medical school
reforms—in the U.S. instigated by Abraham Flexner’s
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report—coincided with a major crisis of Darwin’s
teaching in the early 1900s. While no one doubted
evolution, natural selection as its underlying mechanism
was challenged both by neo-Lamarckians and by the
emerging geneticists who argued that significantly new
forms appeared suddenly by means of random mutation
(Bowler 1992). As “hereditarian” views of the body and
disease came to dominate “environmental” ones around
the turn of the twentieth century, Darwin’s theory and
Galtonian arguments provided a framework for organizing
ideas—and expressing worries—concerning the perceived
increase in the frequency of certain diseases in modern
environments (Pick 1989; Zampieri 2009). Yet although
certain elements of evolutionary biology exercised influ-
ence upon medical disciplines such as anatomy, embryol-
ogy, infectious diseases and immunology, evolutionary
biology itself never became part of the curriculum in the
same way as, for example, biochemistry. Indeed, even in
the most obvious cases of evolutionary processes at work,
such as antibiotic resistance, the language of evolutionary
biology has been generally avoided (Antonovics et al.
2007). Furthermore, at no stage was evolutionary thought
seen as being of value to the practice of public health and
clinical medicine.
But attitudes are now changing, and there has been a
recent rise in interest in the application of evolutionary
biology to understanding the vulnerability of individuals and
populations toward disease. This new approach, known as
“Darwinian medicine” or “evolutionary medicine,” was
pioneered by Randolph Nesse and George C. Williams
in the 1980s. From its beginning, it has been ac-
companied by calls for the inclusion of evolution in
medical education (Williams and Nesse 1991). Their
argument was that understanding evolution was useful
for medical students, practitioners and scientists because
it complemented the answers to the proximate questions
that biomedical and clinical disciplines asked (“What is
the mechanism of disease?”) with ultimate answers
(“Why and how has the mechanism evolved?”). For
example, while the proximate cause of scurvy is lack of
vitamin C in the diet, the ultimate cause is the loss of the
ability in humans to synthesize this nutrient. This
integrated approach to the human body and human
disease would help students bring together anatomical
and physiological facts into a coherent framework, open
research avenues, and offer a new tool for explaining
disease to patients.
Early inquiries into the understanding of and interest
in evolutionary knowledge among medical school
faculty yielded discouraging results. A 2003 survey
found that fewer than half of 50 deans of North
American medical schools saw evolutionary biology as
important knowledge for physicians; only three schools
required a course in evolutionary biology as prerequisite
for matriculation, two offered a course or lecture
sequence focused on evolution, and eight had any
medical school faculty with a primary specialty in
evolutionary biology (Nesse and Schiffman 2003). But recent
years have seen changes. The American Association of
Medical Colleges recently released a report establishing
evolutionary biology as a premedical competency alongside
other foundations such as chemistry and physics, and
pointing to the value of evolutionary approaches within
the medical curriculum itself (AAMC-HHMI Scientific
Foundation for Future Physicians Committee 2009). The
first designated textbook of evolutionary medicine was
recently published; it explicitly considers what compo-
nents of evolutionary medicine have a place in a formal
medical curriculum (Gluckman et al. 2009). The book
provides a framework for clinicians to understand how
evolutionary processes contribute to symptomatology and
disease vulnerability. Several medical schools in Europe,
Australasia, South America, and the U.S. are now
introducing modules on evolutionary medicine into their
core curricula.
While there is a growing recognition that evolution-
ary biology should be taught to medical students, it is
not clear at all how it should be done. In particular,
how should basic evolutionary principles be made
comprehensible to medical students and doctors who
were last introduced to evolution in secondary school or
undergraduate colleges (if at all) and who have little
time or interest for theoretical literature? In this paper,
we suggest an approach to the introduction of the
principles of evolutionary medicine (Box 1) using
diseases/groups of conditions with which students have
become acquainted in their preclinical and clinical
study. This approach is relevant irrespective of whether
the medical course follows an undergraduate degree or
not and irrespective of whether the school uses a
discipline- or a case-based curriculum.
Both case studies, which can serve as exemplars for
additional cases, follow a standardized format in several
sections: proximate mechanisms, affected population,
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first detailed evolutionary history and ultimate explan-
ations and then the pathways by which evolutionary
processes can affect disease risk that this example
illustrates (Box 2). The first example/case study that we
chose is scurvy, as a well-known, relatively simple deficiency
disease. The second example of female reproductive cancers
encompasses a complex set of physiological and pathological
phenomena resulting from the activity of sex hormones upon
bodily tissues. Taken together, they illustrate how evolution-
ary principles can be explained in an accessible and clinically
relevant manner, and how evolutionary biology contributes to
the understanding of disease.
1. An evolutionarily mismatched or novel environment: the individual has been exposed to an environment beyond their evolved capacity to adapt, or to an entirely novel environment or
challenge. 
2. Factors associated with life history strategies: life history strategies are the differing ways in which different species optimize their fitn ess by allocating energy to growth, reproduction
and maintenance.
3. Excessive or uncontrolled defense mechanisms: evolved processes which are normally adaptive (for example, fever or immune responses) may in excess become harmful to the 
individual.   
4. Losing the evolutionary arms race against other species, which for humans in the modern environment are in particular micro-organisms. 
5. Results of evolutionary (‘design’) constraints 
6. An apparently harmful allele is maintained by balancing selection, where heterozygotes for the ‘harmful’ allele have a selective advantage over homozygotes for either the ‘healthy’ or
‘harmful’ alleles (for example, the malaria-associated haemoglobinopathies such as sickle cell disease).   
7. Sexual selection and competition and their consequences. 
8. The outcomes of demographic history, including the influences of drift, bottlenecks, migrations and founder effects.  
1. The mature phenotype is the result of genomic and non-genomic inheritance and the cumulative effect of the developmental environment, and is further influenced by the current
environment. 
2. The history of humans as a species influences our susceptibility to disease. Human history here refers to the influences of drift, bottlenecks and migrations (including founder
effects). Genetic drift refers to random demographic effects in small populations that may eliminate or fix rare alleles, whether they are neutral, favored or deleterious. A
bottleneck is an event that reduces population size and  therefore its genetic diversity. A founder effect refers to the isolation of a small population (for instance by migration)
that reduces genetic diversity. 
3. Selection operates by maximizing reproductive success of individuals. 
4. Selection does not operate to maximize health or longevity. 
5. Humans now live in different ways and in different environments to those where most selective processes affecting the modern human phenotype operated.  
6. Constraints on evolutionary processes in the presence of environmental novelty can lead to ill health.  
7. Definitions of normality/pathology are influenced by the environmental context of the individual and individual variation in phenotype. 
8. There is no preordained plan, purpose or design to evolution. 
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Case I: scurvy
Proximate mechanism
Scurvy is a multi-system disorder most commonly manifested
as inflammation and bleeding of gums, skin, bones, joints and
digestive tract; keratosis of hair follicles (“corkscrew hair”);
anemia, sometimes leading to congestive heart failure; and
nonspecific symptoms such as fatigue (Li et al. 2008). It is
caused by dietary deficiency of vitamin C (ascorbic acid),
found in all fresh fruit and vegetables. The total body pool of
vitamin C is normally about 1,500 mg, and at levels below
350 mg, which equals elimination of vitamin C from the diet
for 60 to 90 days, symptoms of scurvy will appear. The
treatment is repletion of ascorbic acid, which normally leads
to visible improvement within days.
Vitamin C is involved in the hydroxylation of proline to
hydroxyproline and lysine to hydroxylysine, necessary
steps in the formation of collagen, an essential structural
component of the skin, blood vessels, tendons, ligaments
and bone. Vitamin C also has roles in the synthesis of
peptide hormones, norepinephrine, and carnitine, in tyro-
sine metabolism, and in disulfide bond formation in hair. It
also has antioxidant activity.
Affected population
Scurvy, a disorder unknown for most of human history, first
appeared in the age of extended sea voyages between
the sixteenth and eighteenth centuries. Today, the
condition may be found in people eating extreme diets
lacking in fruit and vegetables (the homeless, psychiatric
patients) or those suffering from gastrointestinal conditions,
where the absorption of vitamin C is hindered (Khonsari
et al. 2005).
Evolutionary history, ultimate explanation,
and demonstration of evolutionary principles
The majority of vertebrates are able to synthesize ascorbic
acid from glucose (Chatterjee et al. 1975). The last step in
the pathway requires the enzyme L-gulonolactone oxidase
(GULO), present in almost all organisms with the exception
of some fish, bird, and mammalian species. All the cases
where the species cannot synthesize ascorbate are caused
by mutations in the GULO gene.
Among mammals, inability to synthesize vitamin C is
found mostly in one of the two major primate suborders,
the Anthropoidea (Haplorrhini): tarsiers, monkeys, apes,
and humans. It also occurs in the Order Rodentia: guinea
pigs and capybaras. Until recently, it was also believed that
all families of bats (Order Chiroptera) lacked GULO, but
this has been undermined by a recent study that showed
that some previously unexamined species of bats have the
ability to synthesize vitamin C, albeit at rather low levels
(Cui et al. 2011).
In humans, the loss of synthetic ability is due to a
frameshift mutation in GULO leading to a premature stop
codon. The presence of different mutations in different
species confirms that this gene has mutated a number of
times, and in some species the remnants of the gene are
more recognizable, while in others no traces can be found.
In some passerine bird species, differing mutations that are
not clearly related suggest the likelihood of multiple
mutational events. In contrast, fruit-eating bats share a
common mutation suggesting common ancestry. It seems,
based on the current phylogeny of bats, that they have
reacquired this ability after losing it once, rather than
retaining it throughout (Drouin et al. 2011). Similar
reactivation events have also been proposed for those
passerine bird species that exhibit synthetic capacity.
The study of the mutation in primates illustrates our
phylogenetic history. While the primate suborder of
Haplorrhini cannot produce vitamin C and all share the
same mutation, the other primate suborder of non-tarsier
prosimians, the Strepsirrhini, retained the synthetic
capacity. As these two suborders diverged about 60
million years ago, it is a reasonable presumption that
the mutation occurred in an early Haplorrhine frugivore
ancestor species.
The currently accepted hypothesis is that these mutations
were originally neutral, meaning that deletion of the
vitamin C production pathway had no selective advantage
or disadvantage. All the mutations are located precisely in
GULO, where they affect the ability to make vitamin C
only, rather than elsewhere in the pathway where they
would influence the production of other molecules. All
species which have lost the capacity to synthesize vitamin
C have diverse, yet consistently vitamin C-rich, diets
(Drouin et al. 2011). The daily vitamin C consumption of
gorillas in the wild far exceeds the recommended daily
allowance for adult humans, 1 mg/kg/day. So, if ascorbic
acid was widely available in the human primitive diet, then
selection to retain functioning GULO would have been
relaxed (Lahti et al. 2009).
An alternative hypothesis is that losing the capacity to
synthesize vitamin C was advantageous because vitamin C
synthesis leads to the production of hydrogen peroxide and
the depletion of glutathione (Bánhegyi et al. 1996). As
glutathione is an important antioxidant, and as access to
ascorbate remained unhindered, the loss of internal synthe-
sis took place. However, this alternative hypothesis does
not account for the reacquisition of vitamin C synthetic
capacity in bats which, were the loss of synthetic capacity
advantageous, would have been selected against (Drouin et
al. 2011).
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Pathways of altered disease risk illustrated by this example
& Mismatch pathways leading to disease. A mutation that
was originally neutral may become biologically signif-
icant in a changed environment. Humans normally get
adequate amounts of vitamin C in their diet, and it is
only with extreme shifts from normative food sources
that scurvy appears. In other words, a mutation that was
probably neutral when it first appeared has become
pathological when the environment changed into a
novel one for that lineage, one without vitamin C in
dietary sources.
Case II: female reproductive cancer
Proximate mechanism
Malignant neoplasms of the breast are most commonly
derived from the epithelial lining of the ducts and lobules,
thus classified as ductal or lobular carcinomas. The
susceptibility to carcinogens is directly related to the
epithelial cell proliferation rate and inversely related to the
degree of tissue differentiation. Full maturation of the breast
tissue only occurs after the first pregnancy (Russo et al.
2000), while breastfeeding may allow for the exudation of
pre-neoplastic cells.
Malignancies of the ovary are in most cases derived
from the ovarian epithelium (although some originate in
fallopian tubes); few arise from egg cells or supporting
cells. Like in any other cancer, a series of somatic
mutations or epimutations is required for the neoplastic
potential to be expressed (Greaves 2000).
Affected population
Breast cancer is the most common malignancy in women,
and its incidence has been on the rise in the last several
decades (Jemal et al. 2010). Primary risk factors for breast
cancer include female gender, age over 50 (peri- and
postmenopausal period), nulliparity or no breastfeeding,
hormone-replacement therapy, obesity (but only in post-
menopausal women), alcohol intake, tobacco exposure,
exposure to endocrine disruptors, shift work and lack of
exercise (Rossouw et al. 2002; The ESHRE Capri
Workshop Group 2011). Diet, especially high animal fat
intake, has been suggested but has not been proven as an
independent risk factor.
Genetic factors also have an impact on risk, although the
most common mutations account for only 2–3% of breast
cancers. Best known is the high (up to 87%) risk of lifetime
breast cancer in women carrying one of numerous loss-of-
function mutations in the BRCA1 and BRCA2 tumor
suppressor genes (Thompson et al. 2002; The Breast
Cancer Linkage Consortium 1999). Since molecular phylog-
eny studies suggest that many of the most common alleles at
BRCA1 and BRCA2 arose as new mutations in the relatively
recent (tens of generations) past (Slatkin and Rannala 2000),
the prevalence of these apparently deleterious alleles and
their persistence in the population raises some interesting
issues. Although most of the excess mortality in carriers of
BRCA1 and BRCA2 mutations occurs late in life, after the
reproductive period, sufficient cases occur earlier in life such
that negative selection might be expected to act to decrease
the frequency of the deleterious alleles. That this is not
occurring suggests that the mutations also display beneficial
(fitness-enhancing) effects in the reproductive period that
trade off against their negative (increased cancer susceptibil-
ity) effects in later adulthood, a process known as antago-
nistic pleiotropy. Indeed, a recent study indicated that under
natural fertility conditions, women carrying BRCA1/2 muta-
tions had markedly increased fecundity (and, as expected,
increased post-reproductive mortality) compared with con-
trols (Smith et al. 2011). The increased fecundity was
actualized by decreased interbirth interval and a longer
reproductive period (greater age at last birth); the proximate
(molecular) mechanisms relating altered function of BRCA1/
2 to increased fecundity remain unclear.
While ovarian cancer is much less frequent than breast
cancer, with an incidence rate of around 3% in the female
population, the high mortality associated with this disease
makes it one of the top five causes of cancer death among
women in many developed countries (Jemal et al. 2010).
Primary risk factors include age, nulliparity or no breast-
feeding, no history of oral contraceptives, history of
hormone-replacement therapy, and obesity. Genetic factors
also play a role, as women with a first-degree relative who
has developed the disease have a greater risk, which
increases further when two or more relatives have been
affected. Furthermore, BRCA1 and BRCA2 mutations are
associated with an increased risk of ovarian cancer;
mutations in these genes confer a lifetime risk of ovarian
cancer of up to 66% (Thompson et al. 2002; The Breast
Cancer Linkage Consortium 1999).
Evolutionary history, ultimate explanation, and demonstration
of evolutionary principles
Epidemiological evidence indicates that late menarche,
early first birth, high parity, early menopause, prolonged
lactation reduce the risk of breast as well as ovarian cancer
(Eaton et al. 1994). While all of these features characterized
women in the Paleolithic as well as modern day hunter–
gatherers, modern Western women have early menarche, a
large gap between menarche and first birth, low parity, and
relatively short lactation.
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While the postponement of reproduction, low parity,
and short lactation are outcomes of social, economic,
and political developments that began in the nineteenth
century, lowering of the age at menarche is a phenom-
enon that needs explanation from the evolutionary
perspective. In the developed world, the age at menar-
che has fallen from 17 in the nineteenth century to
about 12.5 years in the late twentieth century (Whincup,
Gilg et al. 2001; Parent et al. 2003; Gluckman and
Hanson 2006; Papadimitriou et al. 2008). It has been
suggested that improved nutrition played a major role in
this phenomenon. Change in the age at menarche is one of
the life history-associated set of mechanisms that shows
plasticity due to environmental modulation (see Box 2,
Pathway 2). A child exposed to placental insufficiency or
poor nutrition in utero may anticipate a hostile external
environment, sometimes including early death and
consequently trade off intrauterine growth for survival
to birth and (eventually) early puberty. At the same
time, a fetus and child fed plentifully is able to increase
fitness by extending the length of the reproductive
period in both directions. So both underfed and well fed
children start menarche early (Parent et al. 2003;
Sloboda et al. 2007; Papadimitriou et al. 2008). Yet, in
later life, the length of the reproductive period as well as
the physiological markers of reproductive function mark-
edly differs (Jasienska et al. 2006a, b). Indeed, a recent
study of natural selection in a contemporary population
has found that the age at menopause is increasing (Byars
et al. 2010).
The increased age at first birth, low number of births,
and short breastfeeding are all part of change in reproduc-
tive behavior that began in the West with the demographic
transition about two centuries ago, but is today underway in
many parts of the world, in particular in East Asia (Frejka
and Sardon 2004; Frejka et al. 2010). Hunter–gatherers
with menarche at 16, average first birth at about 19.5,
breastfeeding for the first three or four years of the child’s
life, an average completed family size of five or six live
births, and menopause at around 47 years of age,
experience only about 188 ovulations (Eaton et al. 1994).
Among the Dogon of Mali, a traditional farming West
African population with a mean of 8.6±3 live births per
woman, women aged 20–34 years had a median of only
two menses each over the two-year study period. Their
median number of menses per lifetime was just 100
(Strassmann 1999). Modern women, by contrast, have
menarche at 12.5, first birth at 24–27 years of age, and a
completed family size of 1.8, so by the age of menopause at
47.5 they may experience close to 500 ovulations (Eaton et
al. 1994). The high number of ovulations, it has been
argued, mechanically injures the ovarian epithelium while
exposing it to locally high hormonal levels, and so
increases the risk of ovarian cancer. The reduction of the
ovarian cancer risk associated with oral contraceptive
use is probably at least partly explainable by ovulation
suppression (Siskind et al. 2000). With regard to breast
cancer, the lack of full maturation of breast tissue in
nulliparous women as well constant proliferative stress on
the ductal and lobular epithelium by estrogen and
progesterone leads to higher rates of carcinogenesis.
The use of hormone-replacement therapy, shown to
increase the risk of breast cancer, extends the exposure
to estrogen and progesterone (Rossouw et al. 2002). At
the same time, reduced lactation also removes the
beneficial loss and renewal of ductal epithelial cells by
lactational “washout”.
Pathways of altered disease risk illustrated by this example
& An evolutionarily mismatched or novel environment.
The marked change in human reproductive behavior,
involving the use of contraception and hormone-
replacement therapy, nulliparity, few and late pregnan-
cies as well as reduced lactation, has created a novel
female endocrine environment that differs from the
environment in which we evolved, an environment of
pregnancy and/or lactational amenorrhea for the
majority of fertile years. The novel environment has
exposed vulnerability to the carcinogenic effects of
sex hormones. The loss of the protective mechanisms
associated with pregnancy, lactational amenorrhea,
and washout as well longer lifetime exposure to
ovulating ovaries has allowed potentially damaged
cells to be retained and turn malignant.
& Life history and trade-off associated factors. The fall in
the age at menarche, driven by improved nutrition, has
extended the potential reproductive period, yet it has
also increased the time that the breast and the ovarian
epithelia are exposed to the mechanical and endocrine
effects of ovulation. Furthermore, because the human
life span is now much longer and there is an age-related
linear increase in the risk of cancer detected in
postmenopausal women, the total lifetime risk of cancer
becomes much larger. Finally, the effects of BRCA1/2
mutations on fecundity and cancer susceptibility pro-
vide an excellent example of antagonistic pleiotropy,
trading off increased reproductive fitness against im-
paired somatic maintenance (tumor suppression).
& Selection operates by maximizing fitness. For all
cancers, neoplastic progression represents a Darwinian
process of mutation, variation, and selection among cell
lineages within individuals, such that tumor cell
lineages with enhanced survival or proliferation capac-
ity will outcompete less “fit” lineages. Such microevo-
lutionary factors play a role in the development of
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resistance to cancer therapy, and understanding the
selection pressures and trade-offs involved may lead to
new treatment approaches.
Conclusion
To medical students, evolutionary principles may seem dry
and distant from their interests and from the rest of the
medical school curriculum. Yet by engaging students’
attention with case studies of diseases familiar from other
subjects, we can introduce them to an evolutionary way of
thinking in a way that is both attractive and educational.
The discussed case studies have shown how two very
different disease categories, a rare vitamin deficiency and
relatively frequent reproductive cancers, may be used to
explain evolutionary concepts and principles and to
elucidate one or more pathways to disease development.
The case of scurvy illustrates the importance of the
phylogenetic approach (“tree-thinking”) as well as showing
how a change of nutritional environment exposes a hitherto
hidden predisposition to disease. The case of reproductive
cancers vividly shows how life history-associated factors,
along with changes in reproductive environment and
demography, dramatically alter disease risk.
This approach, we suggest, creates a framework for
evolutionary thought to become pervasive in the medical
curriculum. Ultimate explanations are of considerable
value in the patient–doctor interaction. Similarly, in public
health a more explicit understanding of evolutionary
principles is of value. We are currently preparing a library
of such case studies, which will be published either as an
online resource or a book, which will include examples of
most disease categories demonstrating all of the pathways
listed in Box 2. We hope that this library will find broad
use among teachers of evolutionary medicine and their
students.
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